Multimodal management - Of value in fulminant acute pancreatitis?

Pancreatology

Volumn 3, Issue 1, 2003, Pages 14-25

  Haraldsen, P ^b   Sun, Z W ^b   Borjesson A ^b   Olanders, K ^b   Lasson, A ^b   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Acute pancreatitis; Endothelial barrier permeability; Monoclonal antibodies; Organ dysfunction; Oxygen free radicals; Platelet activating factor antagonist; Protease inhibitors; Rat; Scavenger

Indexed keywords

ACETYLCYSTEINE; LEXIPAFANT; MONOCLONAL ANTIBODY; OXYGEN RADICAL; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1 MONOCLONAL ANTIBODY; TAURODEOXYCHOLIC ACID; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0037229995     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000069148     Document Type: Article

References (72)

1. Wilson C, Imrie CW: Changing patterns of incidence and mortality from acute pancreatitis in Scotland. Br J Surg 1990;77:731-744.
2. Appelros S, Borgström A: Incidence, aetiology and mortality rate of acute pancreatitis in a defined urban population in Sweden. Br J Surg 1999;8:465-470.
3. Jaakkola M, Nordback I: Pancreatitis in Fin-land between 1970 and 1989. Gut 1993;34:1255-1260.
4. Tenner S, Sica G, Hughes M, Noordhoek E, Feng S, Zinner M, Banks PA: Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997;113:899-903.
5. Wilson PG, Manji M, Neoptolemos JP: Acute pancreatitis as a model of sepsis. J Antimicrob Chemother 1998;41(suppl A):51-63.
6. Tran DD, Cuesta MA, Schneider AJ, Wesdorp RIC: Prevalence and prediction of multiple organ system failure and mortality in acute pancreatitis. J Crit Care 1993;8:145-153.
7. McFadden DW: Organ failure and multiple organ system failure in pancreatitis. Pancreas 1991;6:37-43.
8. Norman JG: The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998;175:76-83.
9. Formela LJ, Galloway SW, Kingsnorth AN: Inflammatory mediators in acute pancreatitis. Br J Surg 1995;82:6-13.
10. Glasbrenner B, Adler G: Pathophysiology of acute pancreatitis. Hepatogastroenterology 1993;40:517-521.
11. Ogawa M: Acute pancreatitis and cytokines: 'Second attack' by septic complication leads to organ failure. Pancreas 1998;16:312-315.
12. Saluja AK, Steer ML: Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion 1999;60(suppl 1): 27-33.
13. Goris RJA: Mediators of multiple organ failure. Intensive Care Med 1990;16(suppl 16):192-196.
14. Goris RJA: Multiple organ failure: Whole body inflammation? Schweiz Med Wochenschr 1989;119:347-353.
15. Norman JG: New approaches to acute pancreatitis: Role of inflammatory mediators. Digestion 1999;60(suppl 1):57-60.
16. Dugernier T, Starkel P, Laterre PF, Reynaert MS: Severe acute pancreatitis: Pathophysiological mechanisms underlying pancreatic necrosis and remote organ failure. Acta Gastroenterol Belg 1996;59:178-185.
17. Graham P, Brass NJ: Multiple organ dysfunction: Pathophysiology and therapeutic modalities. Crit Care Nurse Q 1994;16:8-15.
18. Yurt RW, Lowry SF: Role of the macrophage and endogenous mediators on multiple organ failure; in Deitch EA (ed): Multiple Organ Failure: Pathophysiology and Basic Concepts of Therapy. Stuttgart, Thieme, 1990, pp 60-71.
19. Norman JG, Fink GW, Messina J, Carter G, Franz MG: Timing of tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute pancreatitis. Surgery 1996;120:515-521.
20. Grewal HP, Mohey el Din A, Gaber L, Kotb M, Gaber AO: Amelioration of the physiologic and biochemical changes of acute pancreatitis using an anti-TNF-α polyclonal antibody. Am J Surg 1994;167:214-219.
21. Fink G, Yang J, Carter G, Norman J: Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res 1997;67:94-97.
22. Norman JG, Franz MG, Fink GS, Messina J, Fabri PJ, Gower WR, Carey LC: Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg 1995;221:625-634.
23. Norman J, Franz M, Messina J, Riker A, Fabri PJ, Rosemurgy AS, Gower WR Jr: Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995;117:648-655.
24. Wang X, Sun Z, Börjesson A, Haraldsen P, Aldman M, Deng X, Leveau P, Andersson R: Treatment with lexipafant ameliorates the severity of pancreatic microvascular endothelial barrier dysfunction in rats with acute hemorrhagic pancreatitis. Int J Pancreatol 1999;25:45-52.
25. Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW: Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology 1997;112:960-967.
26. Wang X, Sun Z, Börjesson A, Andersson R: Inhibition of platelet-activating factor, intercellular adhesion molecule 1 and platelet endothelial cell adhesion molecule 1 reduces experimental pancreatitis-associated gut endothelial barrier dysfunction. Br J Surg 1999;86:411-416.
27. Tomazewska R, Dembinski A, Warzecha Z, Banas M, Konturek S, Stachura J: Platelet-activating factor (PAF) inhibitor (TCV-309) reduces caerulein and PAF-induced pancreatitis. A morphologic and functional study in the rat. J Physiol Pharmacol 1992;4:345-352.
28. Tanaka N, Murata A, Uda K, Toda H: Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model. Crit Care Med 1995;23:901-908.
29. Baue AE: Multiple organ failure, multiple organ dysfunction syndrome and systemic inflammatory response syndrome: Why no magic bullets? Arch Surg 1997;132:703-707.
30. Dunon D, Piali L, Imhof BA: To stick or not to stick: The new leukocyte homing paradigm. Curr Opin Cell Biol 1996;8:714-723.
31. Kingsnorth AN: Platelet-activating factor. Scand J Gastroenterol 1996;31(suppl 219):28-31.
32. Newman PJ: Perspective series: Cell adhesion in vascular biology. The biology of PECAM-1. J Clin Invest 1997;99:3-8.
33. Wang X, Deng X, Haraldsen P, Andersson R, Ihse I: Antioxidant and calcium channel blockers counteract endothelial barrier injury induced by acute pancreatitis in rat. Scand J Gastroenterol 1995;30:1129-1136.
34. Deng XM, Wang XD, Andersson R: Endothelial barrier resistance in multiple organs after septic and nonseptic challenges in the rat. J Appl Physiol 1995;78:2052-2061.
35. Sun ZW, Wang XD, Deng XM, Lasson Å, Wallén R, Hallberg E, Andersson R: The influence of intestinal ischemia and reperfusion on bidirectional intestinal barrier permeability, cellular membrane integrity, proteinase inhibitors and cell death in rats. Shock 1998;10:203-212.
36. Kruse P, Hage E, Lasson Å: Proteases and pro-tease inhibitors in taurocholate-induced acute pancreatitis in rats. Int J Pancreatol 1999;25:113-121.
37. Banks P: Predictors of severity in acute pancreatitis. Pancreas 1991;6:7-12.
38. Livingstone T, Deitch E: Multiple organ failure: A common problem in surgical intensive care unit patients. Ann Med 1995;27:13-20.
39. Allardyce DB: Incidence of necrotizing pancreatitis factors related to mortality. Am J Surg 1987;154:295-299.
40. Neuhof H: Actions and interactions of mediator systems and mediators in the pathogenesis of ARDS and multiorgan failure. Acta Anaesthesiol Scand 1991;35(suppl 95):7-14.
41. Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I: Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 2002;30:271-275.
42. Deng XM, Wang XD, Lasson Å, Sun Z, Soltesz V, Andersson R: The involvement of multiple protease-antiprotease systems and gut origin sepsis in zymosan-associated endothelial barrier injury and multiple organ dysfunction in rats. Shock 2001;16:298-303.
43. Denham W, Norman J: The potential role of therapeutic cytokine manipulation in acute pancreatitis. Surg Clin North Am 1999;79:767-781.
44. Anderson BO, Bensard DD, Harken AH: The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg Gynecol Obstet 1991;172:415-424.
45. Yotsumoto F, Manabe T, Kyogoku T, Hirano T, Ohshio G, Yamamoto M, Imamura T, Yoshitomi S: Platelet-activating factor involvement in the aggravation of acute pancreatitis in rabbits. Digestion 1994;55:260-267.
46. Emanuelli G, Montruccio G, Gaia E, Dughera L, Corvetti G, Gubetta L: Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Pathol 1989;134:315-326.
47. Ais G, Lopez-Farre A, Gomez-Garre D, Novo C, Romeo J, Braquet P, Lopez-Novoa JM: Role of platelet activating factor in haemodynamic derangements in acute rodent pancreatitis. Gastroenterology 1992;102:181-187.
48. Fujimura K, Kubuta Y, Ogura M, Yamaguchi T, Binaka T, Tani K, Kitagawa S, Mizuno T, Inoue K: Role of endogenous platelet activating factor in caerulein-induced pancreatitis in rats: Protective effects of PAF antagonist. J Gastroenterol Hepatol 1992;7:199-202.
49. Jancar S, Giacobbi GD, Mariani M, Mencia-Huerta J, Sirois P, Braquet P: Immune complex induced pancreatitis: Effect on BN 52021, a selective antagonist of platelet-activating factor. Prostaglandins 1988;35:357-370.
50. Kingsnorth AN, Galloway SW, Formela LJ: Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-1420.
51. McKay CJ, Curran F, Sharples C, Baxter JN, Imrie CW: Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997;84:1239-1243.
52. Johnson CD, Kingsnorth AN, Imrie CW, McMahon MJ, Neoptolemos JP, McKay C, Toh SKC, Skaife P, Leeder PC, Wilson P, Larvin M, Curtis LD: Double-blind, randomized, placebo-controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-69.
53. Panés J, Granger DN: Leukocyte-endothelial cell interactions: Molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998;114:1066-1090.
54. Bogen S, Pak J, Garifallou M, Deng X, Muller W: Monoclonal antibody to murine PECAM-1 (CD31) block acute inflammation in vivo. J Exp Med 1994;179:1059-1064.
55. Muller W, Weigl S, Deng X, Philips D: PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449-460.
56. Cotgreave IA: N-Acetylcystein: Pharmacological considerations and experimental and clinical applications. Adv Pharmacol 1997;38:205.
57. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R: Improvement by acetylcystein of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 1991;324:1852-1857.
58. Hotz HG, Foitzik T, Rohweder J, Schutzke JD, Fromm M, Runkel NS, Buhr HJ: Intestinal microcirculation and gut permeability in acute pancreatitis: Early changes and therapeutic implications. J Gastrointest Surg 1998;2:518-525.
59. Kusterer K, Poschmann T, Friedemann A, Enghofer M, Zendler S, Usadel KH: Arterial constriction, ischemia-reperfusion and leuko-cyte adherence in acute pancreatitis. Am J Physiol 1993;265:G165-G171.
60. Takase K, Takeyama Y, Nishikawa J, Ueda T, Hori Y, Yamamoto M, Kuroda Y: Apoptotic cell death of renal tubules in experimental severe acute pancreatitis. Surgery 1999;125:411-420.
61. Wang XD, Börjesson A, Sun ZW, Wallen R, Deng XM, Zhang HY, Hallberg E, Andersson R: The association of type II pneumocytes and endothelial permeability with the pulmonary custocyte system in experimental acute pancreatitis. Eur J Clin Invest 1998;28:778-785.
62. Gukovsky I, Gukovskaya AS, Blinman TA, Zaninovic V, Pandol SJ: Early NF-kB activation is associated with hormone-induced pancreatitis. Am J Physiol 1998;275:G1402-G1414.
63. Siebenlist U, Franzoso G, Brown K: Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-455.
64. Grilli M, Chiu J-S, Lenardo MJ: NF-κB and Rel: Participants in multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-62.
65. Lernbecher T, Muller U, Wirth T: Distinct NF-κB/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 1993;365:767-770.
66. Steinle AU, Weidenbach H, Wagner M, Adler G, Schmid RM: NF-kB/Rel activation in cerulein pancreatitis. Gastroenterology 1999;116:420-430.
67. Satoh A, Shimosegawa T, Fujita M, Kimura K, Masamune A, Koizumi M, Toyota T: Inhibition of nuclear factor-κB activation improves the survival of rats with taurocholate pancreatitis. Gut 1999;44:253-258.
68. Dunn JA, Chuanfu L, Tuanzhu H, Race KL, Browder W: Therapeutic modification of nuclear factor κB binding activity and tumor necrosis factor-α gene expression during acute biliary pancreatitis. Am Surg 1997;63:1036-1043.
69. Molnar Z, Shearer E, Lowe D: N-Acetylcystein treatment to prevent the progression of multi-system organ failure: A prospective, randomized, placebo-controlled study. Crit Care Med 1999;27:1100-1104.
70. Walsh TS, Lee A: N-Acetylcystein administration in the critically ill. Int Care Med 1999;25:432-434.
71. Molnar Z, MacKinnon KL, Shearer E, Lowe D, Watson ID: The effect of N-acetylcystein on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients. Intensive Care Med 1998;24:230-235.
72. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C: Treatment with NAC during adult respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997;12:177-182.